A61P 39 - General protective or antinoxious agents

Patents for A61P 39 - General protective or antinoxious agents (19,019)
12/2001
12/13/2001	CA2408670A1 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
12/12/2001	EP1161946A2 Soluble analogs of probucol
12/12/2001	EP1161228A2 Composition comprising isoquercetin and ascorbic acid in a sustained release form
12/12/2001	CN1325692A Medicine with quantitative antiendotoxic action
12/11/2001	US6328966 Transferrin compositions to alleviate the side effects of cytotoxic drugs
12/06/2001	WO2001091682A1 Composition and applicator for topical substance delivery
12/06/2001	WO2001012775A8 25 human secreted proteins
12/06/2001	WO2001000193A3 Zinc ionophores as anti-apoptotic agents
12/05/2001	EP1159280A2 Thiazoloindolinone compounds
12/05/2001	CN1325452A Method for the preparation of quercetin and isoquercetin derivatives
12/05/2001	CN1325393A Method for producing luteolin and luteolin derivatives
12/05/2001	CN1075811C Substituted 2,4-thiazolindione derivative, its preparation method and medicinal composition containing same
12/05/2001	CN1075733C Face-nourishing oral liquor and its preparation method
12/04/2001	US6326370 Use of agonists or antagonists of P2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
12/04/2001	CA2235565C Process for the preparation of rhus verniciflua extract and anti-cancer composition containing same
11/2001
11/29/2001	WO2001090334A2 Drug metabolizing enzymes
11/29/2001	WO2001090070A2 Caspase inhibitors and uses thereof
11/29/2001	WO2001089547A1 Antioxidant and skin preparations for external use
11/29/2001	WO2001089542A2 Composition for improving the cell protection comprising a lipophilic antioxidant and a hydrophilic antioxidant
11/29/2001	WO2001089533A2 Preparation for stabilizing the protective layer on the epithelium of the cornea or the alveoli
11/29/2001	WO2001089520A2 Dehydroascorbic acid formulations and uses thereof
11/29/2001	WO2001089514A2 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
11/29/2001	WO2001089507A1 NOVEL FORMULATIONS OF α-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
11/29/2001	WO2001089502A2 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
11/29/2001	WO2001049305A3 Process for obtaining thylakoids from plants, pure thylakoids and use thereof
11/29/2001	US20010046976 Antimicrobial histone h1 compositions, kits, and methods of use thereof
11/29/2001	US20010046474 Stabilized preparations for use in metered dose inhalers
11/29/2001	CA2429199A1 Drug metabolizing enzymes
11/29/2001	CA2409929A1 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
11/29/2001	CA2409688A1 Method for improving the cell protection
11/29/2001	CA2408781A1 Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone
11/29/2001	CA2408562A1 Dehydroascorbic acid formulations and uses thereof
11/29/2001	CA2408033A1 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
11/29/2001	CA2380935A1 Caspase inhibitors and uses thereof
11/28/2001	EP1157704A1 Remedies or preventives for ischemic reflow failure
11/28/2001	EP1156815A2 Process for extracting polyphenolic antioxidants from purine-containing plants
11/22/2001	WO2001088085A2 Novel bee venom polypeptides and methods of use thereof
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	US20010043952 Anti-oxidant reducing substance and method of producing the same
11/22/2001	CA2398979A1 Novel bee venom polypeptides and methods of use thereof
11/21/2001	EP1155019A1 Substituted porphyrins
11/21/2001	EP1154792A2 Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
11/21/2001	EP1154772A1 Agent for use in transplantation
11/21/2001	EP1154766A2 Use of r-aryl propionic acids for producing medicaments to treat diseases in humans and animals, whereby said diseases can be therapeutically influenced by inhibiting the activation of nf-kappa b
11/21/2001	CN1323215A Inhibition of toxic materials or substances using dendrimers
11/21/2001	CN1322552A Antioxidant compound formulation with beta-carrotene as main component and preparation process
11/20/2001	US6319529 Selenium diet supplement and method of making
11/15/2001	WO2001085677A1 Amino acid derivatives and their use as medicines
11/15/2001	WO2001085256A2 Critical illness neuropathy
11/15/2001	WO2001085182A2 Combined cartilage and plant extract compositions
11/15/2001	WO2001085178A1 Nutritional preparation comprising ribose and folic acid and medical use thereof
11/15/2001	WO2001085169A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085152A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085149A2 Felbamate derived compounds
11/15/2001	WO2001085142A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/15/2001	WO2001012202A3 Use of chemical chelators as reversal agents for drug-induced neuromuscular block
11/15/2001	US20010041711 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazospiro(4.5) decan-4-one, for example; treating pain with reduced side effects of opioid analgesics; affinity for opioid receptor-like (ORL1) receptor
11/15/2001	US20010041178 Preventing airway mucus production by administration of EGF-R antagonists
11/15/2001	US20010041170 Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
11/15/2001	CA2408544A1 Combined marine and plant extract compositions
11/15/2001	CA2408152A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/15/2001	CA2407830A1 Amino acid derivatives and their use as medicines
11/15/2001	CA2407697A1 Felbamate derived compounds
11/15/2001	CA2406549A1 R-eliprodil for treating glaucoma
11/14/2001	CN1321476A Manbing kuaikang series medicines for curing chronic diseases
11/13/2001	US6316478 IL-8 receptor antagonists
11/13/2001	US6316022 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
11/13/2001	US6316002 Germination activated red Ganoderma lucidum spores and method for producing the same
11/08/2001	WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001	WO2000076556A9 High dose radionuclide complexes for bone marrow suppression
11/07/2001	EP1150658A2 Method for controlling liposome size
11/07/2001	EP1150564A1 Inositol derivatives for inhibiting superoxide anion production
11/07/2001	CN1320440A Medicine containing active components of Rhodiola crennulata root and preparing process thereof
11/06/2001	US6313169 Lutein esters having high bioavailability
11/06/2001	US6313107 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
11/06/2001	US6312753 Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses
11/01/2001	WO2001081585A2 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	US20010036919 Preventing airway mucus production by administration of EGF-R antagonists
11/01/2001	CA2406639A1 A thymus expressed human cytochrome p450 (p450tec)
10/2001
10/31/2001	EP0991670B1 Method for fixing or separating ions, in particular of lead, using per(3,6-anhydro) cyclodextrin derivatives
10/31/2001	CN1319392A Pharmaceutical use of gorgonian acid
10/31/2001	CN1073855C 芦荟组合物 Aloe composition
10/30/2001	US6310052 Nitrate esters and their use for neurological conditions
10/30/2001	US6309623 Plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 mum and comprising at least one bioactive agent wherein said suspension medium comprises at least one propellant
10/25/2001	WO2001079480A1 Albumin fusion proteins
10/25/2001	WO2001079444A2 Albumin fusion proteins
10/25/2001	WO2001079443A2 Albumin fusion proteins
10/25/2001	WO2001079442A2 Albumin fusion proteins
10/25/2001	WO2001079271A1 Albumin fusion proteins
10/25/2001	WO2001079258A1 Albumin fusion proteins
10/25/2001	WO2001079256A1 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
10/25/2001	WO2001078718A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage
10/25/2001	WO2001078533A2 Nutritional modules
10/25/2001	WO2001078529A2 Compositions and methods for improving vascular health
10/25/2001	WO2000061541A8 Pharmaceutical compounds
10/25/2001	US20010034362 Pyrrolidine derivatives for vision and memory disorders
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405563A1 Albumin fusion proteins

1 ... 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 ... 191